FDA’s Awkward Transition Continues
Executive Summary
US FDA’s apolitical leadership team is highly unusual – but is it a strength or a weakness in a new Administration? Acting Commissioner Janet Woodcock has been running the agency for nearly six months and there are no signs of the status quo changing any time soon.
You may also be interested in...
US FDA Commissioner: The Waiting Game Continues
The wait for a permanent head of the FDA is continuing into the second year of the Biden Administration. One message is coming through loud and clear: the agency is clearly not a top priority for the White House ... and that might just be a good thing.
US FDA’s Woodcock ‘Managing As If She’s Been Commissioner,’ Not Afraid To Act, CBER Director Says
Peter Marks says Acting Commissioner Janet Woodcock’s tenure running the FDA has been no different than if a permanent commissioner were in place.
CMS Medicare Center Director Seshamani Will Steer Coverage Decision On Aduhelm
Meena Seshamani served in the Obama Administration as head of the health reform office within the Health and Human Services Department.